Patterns of antibiotic exposure and clinical disease activity in inflammatory bowel disease: A 4-year prospective study

Inflammatory Bowel Diseases

Volumn 21, Issue 11, 2015, Pages 2576-2582

  Hashash, Jana G ^a   Chintamaneni, Preethi ^a   Ramos Rivers, Claudia M ^a   Koutroubakis, Ioannis E ^a   Regueiro, Miguel D ^a   Baidoo, Leonard ^a   Swoger, Jason M ^a   Barrie, Arthur ^a   Schwartz, Marc ^a   Dunn, Michael A ^a   Binion, David G ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

antibiotics; disease activity; IBD; quality of life

Indexed keywords

ADALIMUMAB; ANTHELMINTIC AGENT; ANTIDEPRESSANT AGENT; ANTIINFECTIVE AGENT; AZATHIOPRINE; C REACTIVE PROTEIN; CEPHALOSPORIN DERIVATIVE; CERTOLIZUMAB PEGOL; INFLIXIMAB; MACROLIDE; MERCAPTOPURINE; METHOTREXATE; METRONIDAZOLE; NARCOTIC AGENT; PENICILLIN DERIVATIVE; PREDNISONE; QUINOLONE DERIVATIVE; BIOLOGICAL MARKER;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BIOLOGICAL THERAPY; CROHN DISEASE; DEMOGRAPHY; DISEASE ACTIVITY; DRUG EXPOSURE; DRUG USE; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; HEALTH CARE UTILIZATION; HUMAN; INFLAMMATORY BOWEL DISEASE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; REGISTER; SHORT IBD QUESTIONNAIRE; ULCERATIVE COLITIS; AGED; ELECTRONIC HEALTH RECORD; INFLAMMATORY BOWEL DISEASES; MICROBIOLOGY; MICROFLORA; MIDDLE AGED; PATHOLOGY; TERTIARY CARE CENTER;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BIOMARKERS; C-REACTIVE PROTEIN; ELECTRONIC HEALTH RECORDS; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; LONGITUDINAL STUDIES; MALE; MICROBIOTA; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; REGISTRIES; SURVEYS AND QUESTIONNAIRES; TERTIARY CARE CENTERS;

EID: 84945254686     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000534     Document Type: Article

References (44)

1. Ley RE, Peterson DA, Gordon JI. Ecological and evolutionary forces shaping microbial diversity in the human intestine. Cell. 2006;124:837-848.
2. Foxx-Orenstein AE, William D, Chey WD. Manipulation of the gut microbiota as a novel treatment strategy for gastrointestinal disorders. Am J Gastroenterol. 2012;1:41-46.
3. Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology. 2008;134:577-594.
4. De Hertogh G, Aerssens J, Geboes KP, et al. Evidence for the involvement of infectious agents in the pathogenesis of Crohn's disease. World J Gastroenterol. 2008;14:845-852.
5. Chassaing B, Darfeuille-Michaud A. The commensal microbiota and enteropathogens in the pathogenesis of inflammatory bowel diseases. Gastroenterology. 2011;140:1720-1728.
6. Rutgeerts P, Goboes K, Peeters M, et al. Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet. 1991; 337:771-774.
7. D'Haens GR, Geboes K, Peeters M, et al. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology. 1998;114:262-267.
8. Card T, Logan RFA, Rodrigues LC, et al. Antibiotic use and the development of Crohn's disease. Gut. 2004;53:246-250.
9. Shaw SY, Blanchard JF, Bernstein CN. Assocation between the use of antibiotics and new diagnosis of Crohn's disease and ulcerative colitis. Am J Gastroenterol. 2011;106:2133-2142.
10. Hviid A, Svanström H, Frisch M. Antibiotic use and inflammatory bowel diseases in child-hood. Gut. 2011;60:49-54.
11. Isaacs KL, Sartor RB. Treatment of inflammatory bowel disease with antibiotics. Gastroenterol Clin North Am. 2004;33:335-345.
12. Ursing B, Kamme C. Metronidazole in Crohn's disease. Lancet. 1975;1: 775-777.
13. Bernstein LH, Frank MS, Brandt LJ, et al. Healing of perineal Crohn's disease with metronidazole. Gastroenterology. 1980;79:357-365.
14. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults: American college of gastroenterology, practice parameters committee. Am J Gastroenterol. 2010;105:501-523.
15. Mimura T, Rizzello F, Helwig U, et al. Four-week open-label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. Aliment Pharmacol Ther. 2002;16:909-917.
16. Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroenterology. 2004;126:1620-1633.
17. Farrell RJ, LaMont JT. Microbial factors in inflammatory bowel disease. Gastroenterol Clin North Am. 2002;31:41-62.
18. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749-753.
19. Jowett SL, Seal CJ, Barton JR, et al. The short inflammatory bowel disease questionnaire is reliable and responsive to clinically important change in ulcerative colitits. Am J Gastroenterol. 2001;96:2921-2928.
20. Esrailian E, Spiegel BM, Targownik LE, et al. Differences in the management of Crohn's disease among experts and community providers, based on a national survey of sample case vignettes. Aliment Pharmacol Ther. 2007;26:1005-1018.
21. Kronmon MP, Gerber JS, Prasad PA, et al. Variation in antibiotic use for children hospitalized with inflammatory bowel disease exacerbation: a multicenter validation study. J Pediatr Infect Dis Soc. 2012;1:306-313.
22. Bernstein CN, Singh S, Graff LA, et al. A prospective population-based study of trigger of symptomatic flares in IBD. Am J Gastoenterol. 2010; 105:1994-2002.
23. Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology. 1995;108:1617-1621.
24. Allan R, Cooke WT. Evaluation of metronidazole in the management of Crohn's disease. Gut. 1977;18:A422.
25. Lichtenstein GR, Abreu MT, Cohen R, et al; American Gastroenterological Association. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology. 2006;130:940-987.
26. Greenberg GR. Antibiotics should be used as first-line therapy for Crohn's disease. Inflamm Bowel Dis. 2004;10:318-320.
27. Shanahan F, Bernstein CN. Antibiotics as a first-line therapy for Crohn's disease: is there any consensus? Inflamm Bowel Dis. 2004;10:324-326.
28. Hodgson HJF, Bhatti M. Assessment of disease activity in ulcerative colitis and Crohn's disease. Inflamm Bowel Dis. 1995;1:117-134.
29. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462-2476.
30. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002;359: 1541-1549.
31. Rutgeerts P, Diamond RH, Bala M, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc. 2006;63:433-442.
32. Sandborn WJ, Rutgeerts P, Feagan BG, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology. 2009;137:1250-1260.
33. Fuller-Dhomson ESJ. Depression and inflammatory bowel disease: findings from two nationally representative canadian surveys. Inflamm Bowel Dis. 2006;12:697-707.
34. Mittermaier C, Dejaco C, Waldhoer T, et al. Impact of depressive mood on relapse in patients with inflammatory bowel disease: a prospective 18-month follow-up study. Psychosom Med. 2004;66:79-84.
35. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003;289:3095-3105.
36. Nahon S, Lahmek P, Durance C. Risk factors of anxiety and depression in inflammatory bowel disease. Inflamm Bowel Dis. 2012;18:2086-2091.
37. Schirbel A, Reichert A, Roll S, et al. Impact of pain on health-related quality of life in patients with inflammatory bowel disease. World J Gastroenterol. 2010;16:3168-3177.
38. Casellas F, López-Vivancos J, Casado A, et al. Factors affecting health related quality of life of patients with inflammatory bowel disease. Qual Life Res. 2002;11:775-781.
39. Gibson PR, Vaizey C, Black CM, et al. Relationship between disease severity and quality of life and assessment of health care utilization and cost for ulcerative colitis in Australia: a cross-sectional observational study. J Crohns Colitis. 2014;8:598-606.
40. Aberra FN, Brensinger CM, Bilker WB, et al. Antibiotic use and the risk of flare of inflammatory bowel disease. Clin Gastroenterolo Hepatol. 2005;3:459-465.
41. Shen B, Achkar JP, Lashner BA, et al. A randomized clinical trial of ciprofloxacin and metronidazole to treat acute pouchitis. Inflamm Bowel Dis. 2001;7:301-305.
42. Gilat T, Suissa A, Leichtman G, et al. A comparative study of metro nidazole and sulfasalazine in active, not severe, ulcerative colitis. J Clin Gastroenterol. 1987;9:415-417.
43. Chapman RW, Selby WS, Jewell DP. Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. Gut. 1986;27:1210-1212.
44. Mantzaris GJ, Petraki K, Archavlis E, et al. A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis. Scand J Gastroenterol. 2001;36: 971-974.